Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Kirsten rat sarcoma virus (KRAS) is a frequently mutated oncogene in various cancers, particularly gastrointestinal malignancies.
• KRAS protein, a GTPase, regulates cell signaling pathways, and was historically considered undruggable.
• Recent advancements have led to the development of small-molecule inhibitors targeting specific KRAS mutations, notably KRAS G12C.

Purpose of the Study:

• To review the current landscape and emerging strategies for targeting KRAS mutations in gastrointestinal cancers.
• To highlight the clinical activity and potential of novel KRAS inhibitors, including KRAS G12C inhibitors.
• To discuss the evolving therapeutic strategies and future directions for KRAS-targeted therapies in gastrointestinal malignancies.

Main Methods:

• Review of recent clinical trials and preclinical studies on KRAS inhibitors.
• Analysis of the efficacy of KRAS G12C inhibitors in combination therapies.
• Exploration of novel inhibitors targeting various KRAS alterations.

Main Results:

• KRAS G12C inhibitors have demonstrated significant clinical activity in pancreatic ductal adenocarcinoma and colorectal cancer, often in combination with anti-EGFR antibodies.
• Early data suggest encouraging results for other gastrointestinal cancers, with ongoing investigations into various combination strategies.
• New KRAS G12C inhibitors and inhibitors for other KRAS alterations are entering clinical trials, employing innovative mechanisms.

Conclusions:

• Novel KRAS inhibitors, including those targeting KRAS G12C, represent a significant breakthrough in treating KRAS-mutated gastrointestinal cancers.
• The development of targeted therapies for KRAS alterations, especially less common ones in gastrointestinal cancers, holds potential for groundbreaking advances.
• The rapidly evolving field of KRAS inhibitors is poised to transform the therapeutic landscape for gastrointestinal cancers, offering improved survival outcomes.